Drug Profile
Pegfilgrastim biosimilar - NAL Pharma
Alternative Names: NAL 3760; PEG-GCSF - NAL PharmaLatest Information Update: 25 Nov 2021
Price :
$50
*
At a glance
- Originator NAL Pharma
- Class Antineoplastics; Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Recombinant proteins
- Mechanism of Action Granulocyte colony stimulating factor receptor agonists; Granulocyte colony-stimulating factor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Neutropenia
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for preclinical development in Neutropenia in Unknown (SC, Injection)
- 11 Aug 2016 Pegfilgrastim biosimilar - NAL Pharma is available for licensing as of 11 Aug 2016. http://www.nalpharma.com/aboutUs.php?id=2&lang=en
- 11 Aug 2016 Preclinical trials in Neutropenia (SC)